Eva Maria Fenyo
Overview
Explore the profile of Eva Maria Fenyo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
747
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Esbjornsson J, Mansson F, Kvist A, da Silva Z, Andersson S, Fenyo E, et al.
Lancet HIV
. 2018 Nov;
PMID: 30392769
Background: HIV type 2 (HIV-2) is considered more benign and has fewer pathogenic consequences than HIV type 1 (HIV-1) for most infected individuals. However, reliable estimates of time to AIDS...
2.
Sheik-Khalil E, Bray M, Sahin G, Scarlatti G, Jansson M, Carpenter A, et al.
BMC Infect Dis
. 2014 Sep;
14:472.
PMID: 25176034
Background: Standardized techniques to detect HIV-neutralizing antibody responses are of great importance in the search for an HIV vaccine. Methods: Here, we present a high-throughput, high-content automated plaque reduction (APR)...
3.
Esbjornsson J, Mansson F, Kvist A, Isberg P, Biague A, da Silva Z, et al.
AIDS
. 2014 May;
28(7):949-57.
PMID: 24812673
Objective: To compare survival times of HIV-1 single and HIV-1 and HIV-2 dual-infected individuals. Design: Prospective open cohort study. Methods: We analysed data from 259 HIV-1-seroincident cases (either HIV-1 single...
4.
Esbjornsson J, Mansson F, Kvist A, Isberg P, Nowroozalizadeh S, Biague A, et al.
AIDS
. 2014 Jan;
28(4):614-5.
PMID: 24469002
No abstract available.
5.
Mild M, Gray R, Kvist A, Lemey P, Goodenow M, Fenyo E, et al.
Infect Genet Evol
. 2013 May;
19:369-77.
PMID: 23672855
In approximately 70% of individuals infected with HIV-1 subtype B, the virus switches coreceptor use from exclusively CCR5 use (R5 virus) to either inclusion of or exclusively CXCR4 use (X4...
6.
Sahin G, Mansson F, Palm A, Vincic E, Da Silva Z, Medstrand P, et al.
AIDS Res Hum Retroviruses
. 2012 Oct;
29(3):470-8.
PMID: 23088167
Human immunodeficiency virus type 2 (HIV-2) is less transmissible and less pathogenic compared to HIV-1 and, when matched for CD4(+) T cell count, the plasma viral load in HIV-2-infected individuals...
7.
Sahin G, Holmgren B, Sheik-Khalil E, Da Silva Z, Nielsen J, Nowroozalizadeh S, et al.
J Virol
. 2012 Oct;
87(1):273-81.
PMID: 23077299
Human immunodeficiency virus type 2 (HIV-2)-infected individuals develop immunodeficiency with a considerable delay and transmit the virus at rates lower than HIV-1-infected persons. Conceivably, comparative studies on the immune responsiveness...
8.
Esbjornsson J, Mansson F, Kvist A, Isberg P, Nowroozalizadeh S, Biague A, et al.
N Engl J Med
. 2012 Jul;
367(3):224-32.
PMID: 22808957
Background: Progressive immune dysfunction and the acquired immunodeficiency syndrome (AIDS) develop in most persons with untreated infection with human immunodeficiency virus type 1 (HIV-1) but in only approximately 20 to...
9.
Heyndrickx L, Heath A, Sheik-Khalil E, Alcami J, Bongertz V, Jansson M, et al.
PLoS One
. 2012 May;
7(5):e36438.
PMID: 22590544
Background: Neutralizing antibodies provide markers for vaccine-induced protective immunity in many viral infections. By analogy, HIV-1 neutralizing antibodies induced by immunization may well predict vaccine effectiveness. Assessment of neutralizing antibodies...
10.
Sahin G, Holmgren B, Da Silva Z, Nielsen J, Nowroozalizadeh S, Esbjornsson J, et al.
J Virol
. 2011 Nov;
86(2):961-71.
PMID: 22072782
HIV-2 has a lower pathogenicity and transmission rate than HIV-1. Neutralizing antibodies could be contributing to these observations. Here we explored side by side the potency and breadth of intratype...